Taino Maibo's ten-year advisory agreement has been questioned, with partner Zhao Jian involved in supplier referrals and petrochemical background

Rui Finance Liu Zhiying On March 24, Zhuhai Taino Mabo Pharmaceutical Co., Ltd. (hereinafter referred to as Taino Mabo) disclosed the reply to the second round of inquiry letters from the review, planning to list on the STAR Market. The sponsor is Huatai United Securities, with representatives Shen Zhongjie and Tang Dawei. The accounting firm is Ernst & Young Hua Ming.

The prospectus shows that Taino Mabo was established in 2015 with a registered capital of 391 million yuan. The legal representative is HUAXIN LIAO. It is an innovative biopharmaceutical company focused on blood product replacement therapies for the global market. As of the signing date of this prospectus, the company has developed multiple candidate antibody drugs, including the world’s first-in-class Stetudata monoclonal antibody injection, which has been approved for listing.

According to the first-round reply and the prospectus: Taino Mabo signed a ten-year “Consulting Service Agreement” with Zhao Jian, who mainly provides referral services for suppliers and other related services.

In response, the Shanghai Stock Exchange requires Taino Mabo to disclose: the duration and specific content of Zhao Jian’s services to the company, whether the referral services are legal and compliant, whether he is still providing consulting services, and whether Zhao Jian and his former or current companies have any other undisclosed dealings with the company.

Taino Mabo states that in 2017, when the company was in its startup phase, to better meet the needs of R&D and financing development, the company signed a 10-year “Consulting Service Agreement” with Zhao Jian based on his extensive resources and connections in the pharmaceutical industry. The agreement stipulates that Zhao Jian should provide relevant consulting services according to the company’s needs in R&D and operational activities, helping the company refer suitable R&D partners, experts, consumables suppliers, R&D service providers, senior talents, etc., to support the company’s development. During the service period, Zhao Jian’s time and specific content of services are as follows:

When providing referral services, Zhao Jian diligently offers consulting services based on the company’s needs and the agreement, strictly complying with relevant laws and regulations. There is no conduct of commercial bribery, unfair competition, or other improper means to obtain benefits during the referral process. The company and the suppliers or customers referred by Zhao Jian do not engage in illegal activities such as commercial bribery or disguised benefit transfers. Since the signing of the service agreement, neither the company nor Zhao Jian has been penalized, prosecuted, or involved in investigations related to the referral services. The referral services are legal and compliant.

As of the date of this reply, because the service period of the “Consulting Service Agreement” has not yet expired, Zhao Jian continues to provide relevant consulting services based on the company’s development needs, such as ongoing referrals of distributors and external promotion service providers.

As of the date of this reply, Zhao Jian’s employment history is detailed as follows, and Zhao Jian and his former or current companies have no other undisclosed dealings with the company.